Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
NCT ID | NCT06710288 |
Title | A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In Participants With Recurrent Platinum-Resistant High-Grade Ovarian Cancer |
Recruitment | Recruiting |
Gender | female |
Phase | Phase II |
Variant Requirements | No |
Sponsors | ImmunityBio, Inc. |
Indications | |
Therapies | |
Age Groups: | adult | senior |
Covered Countries | USA |